A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms SUNRISE
- 06 Jun 2017 Results assessing the feasibility and tolerability of high dose, once weekly (1w) or once every two weeks (2w) sunitinib in patients with advanced solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 17 Mar 2017 Planned End Date changed from 27 Jul 2016 to 1 Dec 2017.
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology. (n = 20)